Home  /  Resource Library  /  Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and >65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and >1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and >65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and >1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

ASH 2022